sunitinib + gemcitabine + paclitaxel + pembrolizumab

SGP+P is a combination chemo-immunotherapy regimen consisting of sunitinib, gemcitabine, paclitaxel, and pembrolizumab. It has been primarily investigated for the treatment of advanced or metastatic urothelial carcinoma (bladder cancer). The regimen integrates the multi-targeted tyrosine kinase inhibitor sunitinib, which inhibits vascular endothelial growth factor receptors (VEGFR) and platelet-derived growth factor receptors (PDGFR) to disrupt tumor angiogenesis, with the cytotoxic chemotherapy agents gemcitabine and paclitaxel. Gemcitabine acts as a nucleoside analog that inhibits DNA synthesis, while paclitaxel stabilizes microtubules to prevent cell division. The addition of pembrolizumab, a monoclonal antibody targeting the programmed death receptor-1 (PD-1), serves to block the interaction between PD-1 and its ligands (PD-L1 and PD-L2), thereby reactivating the patient's immune system to recognize and attack malignant cells. This multi-pronged approach aims to overcome resistance and improve outcomes in patients with aggressive urothelial malignancies.

Other names

SGP plus pembrolizumabSGP-pembrolizumab